Study published on new drug class targeting ACVR1 mutation for DIPG Scientists at The Institute of Cancer Research, London, along with colleagues at the Structural Genomics Consortium in Oxford, have published their findings on a new drug class that can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumours in mice. Mutated versions [...]
Listen to a recording of the April 24th 2019 Scientific Update Meeting Listen to our scientists and collaborators discuss the latest progress in M4K Pharma’s quest for a medicine for DIPG- a deadly children’s brain cancer. Everyone is invited to dial-in and join our live meetings. To find out when our next [...]
Recording of M4K Pharma’s Scientific Update Meeting – April 10th, 2019 Listen to our scientists and collaborators discuss the latest progress in M4K Pharma’s quest for a medicine for DIPG- a deadly children’s brain cancer. Everyone is invited to dial-in and join our live meetings. To find out when our next meeting [...]
Recording of M4K Pharma’s Scientific Update Meeting – March 6th, 2019 Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join our live meetings. To find out when our next meeting will be, follow [...]
Medicines for Neurodegeneration (M4ND) Pharma launched! Following in the path of M4K Pharma, M4ND will tackle neurodegenerative diseases such as Parkinson’s disease, thanks to funding from the Krembil Foundation, and will commit to open science practises, open sharing of data, and affordable pricing. https://www.utoronto.ca/news/u-t-researcher-s-open-science-drug-discovery-model-expands-neurodegenerative-diseases
Richard Gold (McGill University) and Max Morgan (SGC, M4k Pharma) penned an opinion piece in the Globe and Mail discussing how open science projects with no patents can result in local economic development, citing the recent $1Billion investment deal that Celgene signed with the Ontario Institute for Cancer Research (OICR) and their commercialization arm FACIT [...]
Recording of M4K Pharma's Scientific Update Meeting - December 4th, 2018 Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. In this meeting, the team provides a comprehensive summary of the project accomplishments at the one year [...]
Regulatory exclusivity as a primary intellectual property and commercial asset How can a company take advantage of regulatory exclusivity to launch an open science drug discovery program? Max Morgan et al explain in their paper Ideation and implementation of an open science drug discovery business model - M4K Pharma published in Welcome Open Research this month. Comparing [...]
Recording of M4K Pharma's Scientific Update Meeting - November 6th, 2018. Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join the live meetings. To find out when our next meeting will be, follow [...]
Recording of M4K Pharma's Scientific Update Meeting - September 11th, 2018. Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join the live meetings. To find out when our next meeting will be, follow [...]
